HUMANIGEN, INC

2022 Q4 Form 10-Q Financial Statement

#000121465922013718 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.16M $24.73M $76.50M
YoY Change -85.5% -67.68% -16.33%
Cash & Equivalents $10.16M $24.73M $76.50M
Short-Term Investments
Other Short-Term Assets $950.0K $1.153M $1.347M
YoY Change -0.52% -14.4% 117.26%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.11M $25.88M $77.85M
YoY Change -84.35% -66.76% -15.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 28.57%
Total Long-Term Assets $90.00K $90.00K $90.00K
YoY Change 0.0% 0.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $11.11M $25.88M $77.85M
Total Long-Term Assets $90.00K $90.00K $90.00K
Total Assets $11.20M $25.97M $77.94M
YoY Change -84.25% -66.68% -15.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $40.52M $53.34M $45.96M
YoY Change -9.35% 16.05% 425.88%
Accrued Expenses $14.79M $22.16M $18.60M
YoY Change -25.61% 19.14% 203.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $56.19M $76.39M $68.71M
YoY Change -18.23% 11.17% 362.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $24.82M
YoY Change -100.0%
Other Long-Term Liabilities $1.766M $1.986M $2.054M
YoY Change 73.48% -3.31%
Total Long-Term Liabilities $0.00 $1.986M $24.82M
YoY Change -100.0% -92.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.19M $76.39M $68.71M
Total Long-Term Liabilities $0.00 $1.986M $24.82M
Total Liabilities $57.96M $78.37M $95.58M
YoY Change -38.83% -18.0% 542.78%
SHAREHOLDERS EQUITY
Retained Earnings -$681.8M -$686.2M
YoY Change 11.57%
Common Stock $119.0K $119.0K
YoY Change 85.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$46.77M -$52.41M -$17.64M
YoY Change
Total Liabilities & Shareholders Equity $11.20M $25.97M $77.94M
YoY Change -84.25% -66.68% -15.41%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.12
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56997039 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59486626 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79179209 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35798
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0557236
dei Entity Address Address Line1
EntityAddressAddressLine1
830 Morris Turnpike
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Short Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07078
dei City Area Code
CityAreaCode
(973)
dei Local Phone Number
LocalPhoneNumber
200-3100
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
HGEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
119080135 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24725000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70016000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1153000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
25878000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
70971000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000 usd
CY2022Q3 us-gaap Assets
Assets
25968000 usd
CY2021Q4 us-gaap Assets
Assets
71061000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
53340000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
44698000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22163000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19882000 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
884000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4145000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
76387000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
68725000 usd
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1986000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1018000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25006000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
78373000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
94749000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119080135 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119080135 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64027629 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64027629 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
119000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
64000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633675000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587327000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-686199000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-611079000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-52405000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23688000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25968000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71061000 usd
CY2022Q3 us-gaap Revenues
Revenues
221000 usd
CY2021Q3 us-gaap Revenues
Revenues
1036000 usd
us-gaap Revenues
Revenues
2293000 usd
us-gaap Revenues
Revenues
2558000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18929000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60811000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62587000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
183757000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4013000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6204000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12307000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19228000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
22942000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
67015000 usd
us-gaap Operating Expenses
OperatingExpenses
74894000 usd
us-gaap Operating Expenses
OperatingExpenses
202985000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22721000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-65979000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-72601000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-200427000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1298000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
751000 usd
us-gaap Interest Expense
InterestExpense
2800000 usd
us-gaap Interest Expense
InterestExpense
1516000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
326000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
281000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1166000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23693000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-66739000 usd
us-gaap Net Income Loss
NetIncomeLoss
-75120000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203109000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.56
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
101422027 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59486626 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79179209 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56997039 shares
us-gaap Net Income Loss
NetIncomeLoss
-75120000 usd
us-gaap Net Income Loss
NetIncomeLoss
-203109000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4560000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3815000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
374000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
198000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
872000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8642000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
30596000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2281000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15427000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2293000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1983000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62128000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-151786000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41843000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134140000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1965000 usd
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
24444000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
25006000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16837000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
160549000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-45291000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8763000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70016000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67737000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24725000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76500000 usd
us-gaap Interest Paid Net
InterestPaidNet
1319000 usd
us-gaap Interest Paid Net
InterestPaidNet
961000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23688000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18374000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1543000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21278000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25049000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3475000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1635000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30149000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-50088000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19994000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1382000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23693000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-52405000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45545000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36106000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
429000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-65567000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
17023000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94172000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1432000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1871000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-70803000 usd
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
75500000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
43695000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3862000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1434000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-66739000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-17644000 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
24700000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8323064 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4687088 shares
CY2020 hgen Upfront License Fee Amount
UpfrontLicenseFeeAmount
6000000 usd
CY2020 hgen Milestone License Payments
MilestoneLicensePayments
14000000 usd
CY2021Q1 hgen Milestone License Payments
MilestoneLicensePayments
6000000 usd
CY2021Q1 hgen Net Of Withholding Taxes And Other Fees And Royalties
NetOfWithholdingTaxesAndOtherFeesAndRoyalties
4500000 usd
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
hgen Upfront License Fee Amount
UpfrontLicenseFeeAmount
6000000 usd
hgen Net Of Withholding Taxes And Other Fees And Royalties
NetOfWithholdingTaxesAndOtherFeesAndRoyalties
4500000 usd
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
800000 usd
CY2022Q3 hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
200000 usd
hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
2300000 usd
CY2021Q3 hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
1000000 usd
hgen Revenue From Contracts With Customer Including Assessed Tax
RevenueFromContractsWithCustomerIncludingAssessedTax
2600000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8291826 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.06
CY2022Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1200000 usd
CY2022Q4 hgen Lenzilumab Vials
lenzilumabVials
630000 vials
hgen Lenzilumab Vials
lenzilumabVials
630000 vials
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4429906 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4708969 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.57
hgen Cancelledforfeited Options
CancelledforfeitedOptions
-820024 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
27025 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1382000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1434000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4560000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3815000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
hgen Thermo Litigation Description
ThermoLitigationDescription
Thermo has 594,000 vials of lenzilumab that are in production, for which material has not yet been released by the Company because the batches produced are out of specification. Thermo recently filed a lawsuit against the Company in Delaware Superior Court (Patheon Biologics, Inc. v. Humanigen, Inc., Case No. N22C-10-185 MMJ) for $25.9 million. The Company denies Thermo’s claims and assertions and will vigorously defend against them.
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.56
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
101422027 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Issuance Of Long Term Debt And Capital Securities Net
ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001293310

Files In Submission

Name View Source Status
0001214659-22-013718-index-headers.html Edgar Link pending
0001214659-22-013718-index.html Edgar Link pending
0001214659-22-013718.txt Edgar Link pending
0001214659-22-013718-xbrl.zip Edgar Link pending
chart.jpg Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hgen-20220930.htm Edgar Link pending
hgen-20220930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hgen-20220930_cal.xml Edgar Link unprocessable
hgen-20220930_def.xml Edgar Link unprocessable
hgen-20220930_lab.xml Edgar Link unprocessable
hgen-20220930_pre.xml Edgar Link unprocessable
hgen-20220930_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending